Finance

Lists
DRREDDY:NSE
Dr Reddy's Laboratories Ltd
1 199,80 INR
+1,68%
(+19,80) 1D
9 ოქტ, 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for DRREDDY...
Open
1 180,00 INR
High
1 200,80 INR
Low
1 172,00 INR
Mkt. cap
999,42 მლრ.
Avg. vol.
1,81 მლნ.
Volume
1,51 მლნ.
Dividend
0,67%
Quarterly dividend
2,00 INR
Ex-dividend date
10 ივლ. 2026
P/E ratio
31,03
52-wk high
1 414,90 INR
52-wk low
1 101,00 INR
EPS
38,67 INR
Shares outstanding
166,06 მლნ.
No. of employees
28 ათ.
Open
1 180,00 INR
High
1 200,80 INR
Low
1 172,00 INR
Mkt. cap
999,42 მლრ.
Avg. vol.
1,81 მლნ.
Volume
1,51 მლნ.
Dividend
0,67%
Quarterly dividend
2,00 INR
Ex-dividend date
10 ივლ. 2026
P/E ratio
31,03
52-wk high
1 414,90 INR
52-wk low
1 101,00 INR
EPS
38,67 INR
Shares outstanding
166,06 მლნ.
No. of employees
28 ათ.
News stories
From web sources and news partners
Profile
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology. Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. By 2007, Dr. Wikipedia
About Dr Reddy's Laboratories Ltd
CEOErez Israeli
Employees27,5 ათ.
Founded1984
Headquartersჰაიდარაბადი, ანდჰრა-პრადეში, ინდოეთი
SectorPharmaceutical industry
Next call 13 დღეში
პარ, 23 ოქტ, 16:00
Fiscal period
Q2 2027
- / 8,93 INR
Revenue / Est. (INR)
- / 85,97 მლრდ.
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
88,05 მლრდ.
87,27 მლრდ.
75,16 მლრდ.
80,70 მლრდ.
Cost of goods sold
39,91 მლრდ.
40,46 მლრდ.
41,47 მლრდ.
43,16 მლრდ.
Cost of revenue
39,91 მლრდ.
40,46 მლრდ.
41,47 მლრდ.
43,16 მლრდ.
Research and development expenses
6,20 მლრდ.
6,15 მლრდ.
5,46 მლრდ.
5,77 მლრდ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
26,44 მლრდ.
26,92 მლრდ.
27,76 მლრდ.
28,82 მლრდ.
Operating expense
31,90 მლრდ.
32,48 მლრდ.
32,53 მლრდ.
34,11 მლრდ.
Total operating expenses
71,81 მლრდ.
72,94 მლრდ.
74,00 მლრდ.
77,27 მლრდ.
Operating income
16,24 მლრდ.
14,33 მლრდ.
1,16 მლრდ.
3,43 მლრდ.
Other non operating income
1,28 მლრდ.
570,00 მლნ.
512,00 მლნ.
-
EBT including unusual items
18,35 მლრდ.
15,43 მლრდ.
1,99 მლრდ.
5,53 მლრდ.
EBT excluding unusual items
17,81 მლრდ.
15,52 მლრდ.
1,82 მლრდ.
4,09 მლრდ.
Income tax expense
4,08 მლრდ.
3,53 მლრდ.
-214,00 მლნ.
1,18 მლრდ.
Effective tax rate
22,24%
22,90%
-10,75%
21,32%
Other operating expenses
-740,00 მლნ.
-591,00 მლნ.
-693,00 მლნ.
-477,00 მლნ.
Net income
14,37 მლრდ.
12,10 მლრდ.
2,20 მლრდ.
4,44 მლრდ.
Net profit margin
16,32%
13,86%
2,93%
5,50%
Earnings per share
17,87
14,77
5,74
5,33
Interest and investment income
912,00 მლნ.
796,00 მლნ.
890,00 მლნ.
999,00 მლნ.
Interest expense
-907,00 მლნ.
-944,00 მლნ.
-1,06 მლრდ.
-1,26 მლრდ.
Net interest expenses
5,00 მლნ.
-148,00 მლნ.
-167,00 მლნ.
-256,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
21,29 მლრდ.
19,54 მლრდ.
5,03 მლრდ.
8,80 მლრდ.
Gain or loss from assets sale
-308,00 მლნ.
-179,00 მლნ.
-2,10 მლრდ.
-368,00 მლნ.
AI content may include mistakes. Learn more
Google აპები